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Glutamate is the major excitatory transmitter in the brain. Vesicular glutamate transporters
(VGLUT1-3) are responsible for uploading glutamate into synaptic vesicles. VGLUT1
and VGLUT2 are considered as specific markers of canonical glutamatergic neurons,
while VGLUT3 is found in neurons previously shown to use other neurotransmitters
than glutamate. Although there exists a rich literature on the localization of these
glutamatergic markers in the rodent brain, little is currently known about the distribution
of VGLUT1-3 in the human brain. In the present study, using subtype specific probes and
antisera, we examined the localization of the three vesicular glutamate transporters in the
human brain by in situ hybridization, immunoautoradiography and immunohistochemistry.
We found that the VGLUT1 transcript was highly expressed in the cerebral cortex,
hippocampus and cerebellum, whereas VGLUT2 mRNA was mainly found in the thalamus
and brainstem. VGLUT3 mRNA was localized in scarce neurons within the cerebral
cortex, hippocampus, striatum and raphe nuclei. Following immunoautoradiographic
labeling, intense VGLUT1- and VGLUT2-immunoreactivities were observed in all regions
investigated (cerebral cortex, hippocampus, caudate-putamen, cerebellum, thalamus,
amygdala, substantia nigra, raphe) while VGLUT3 was absent from the thalamus and
cerebellum. This extensive mapping of VGLUT1-3 in human brain reveals distributions that
correspond for the most part to those previously described in rodent brains.
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INTRODUCTION
Glutamate, the major excitatory neurotransmitter in the brain,
has been implicated in many neurological and psychiatric dis-
orders (Fonnum, 1984). This amino acid is present in all cell
types and participates in numerous cellular functions, from pro-
tein biosynthesis to various aspects of metabolism. As a bona fide
neurotransmitter, glutamate must first be uploaded into synaptic
vesicles within presynaptic terminals before undergoing regulated
release at the synaptic cleft (Fonnum et al., 1998; Gasnier, 2000).
Proton-dependent carriers, named vesicular glutamate trans-
porters (VGLUTs) 1–3, are responsible for the vesicular accu-
mulation of glutamate (for review see El Mestikawy et al., 2011;
Hnasko and Edwards, 2012). These key actors of excitatory neu-
rotransmission were first identified and characterized in rodents
and humans (Ni et al., 1994; Bellocchio et al., 1998, 2000; Aihara
et al., 2000; Takamori et al., 2000, 2001, 2002; Fremeau et al., 2001,
2002; Gras et al., 2002; Schafer et al., 2002; Varoqui et al., 2002).
Takamori and colleagues established more than a decade ago that
the expression of a vesicular glutamate transporter in neurons
was sufficient to confer a “glutamatergic phenotype” (Takamori
et al., 2000, 2001). Moreover, alteration of VGLUT levels has been
shown to modify the glutamate content of synaptic vesicles and
hence the strength of excitatory synaptic transmission (Daniels
et al., 2004). VGLUTs are thus key anatomical and functional
markers of glutamatergic transmission.
With the advent of genetically engineered mice, specific fea-
tures and functions of the 3VGLUTs have recently been identified
(for review see Wallen-Mackenzie et al., 2010). VGLUT1-
knockout mice (VGLUT1-KO) die after weaning (Fremeau et al.,
2004b; Wojcik et al., 2004) while VGLUT2-KO die immediately
after birth from respiratory insufficiency (Moechars et al., 2006;
Wallen-Mackenzie et al., 2006). These findings have clearly estab-
lished that VGLUT1 and VGLUT2 are engaged in the regulation
of vital functions. In contrast, VGLUT3-KO mice have a normal
life expectancy despite being deaf and developing anxiety and dis-
crete basal locomotor phenotypes (Ruel et al., 2008; Seal et al.,
2008; Amilhon et al., 2010). Recent studies using constitutive or
conditional knock-out mouse models have further established
that the 3VGLUTs are involved in cognition, mood regulation,
locomotor activity, reward, and pain (for reviews, see Seal and
Edwards, 2006; Benarroch, 2010; Wallen-Mackenzie et al., 2010;
El Mestikawy et al., 2011).
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The anatomical distribution of the 3VGLUTs has been thor-
oughly characterized in the mature rodent brain (for review see
El Mestikawy et al., 2011). To briefly summarize, a large popu-
lation of cortical excitatory neurons expresses VGLUT1, whereas
subcortical glutamatergic neurons express VGLUT2 (Aihara et al.,
2000; Herzog et al., 2001). In addition, VGLUT2 is also found in
some cortical neurons (predominantly layer IV) while VGLUT1
is expressed in some thalamic nuclei (Fremeau et al., 2001).
Together, VGLUT1- and VGLUT2-expressing neurons represent
the bulk of “canonical” glutamatergic neurons in the brain.
VGLUT1 represents the major subtype and accounts for approxi-
mately 80% of total vesicular transport of glutamate in the brain
(Fremeau et al., 2004b). Combined, VGLUT1- and VGLUT2-
immunoreactive (-IR) neurons extend nearly ubiquitous pro-
jections throughout the brain. In contrast, the distribution of
VGLUT3-immunoreactivity is much more discrete, as it is found
in discrete population of neurons using other transmitters than
glutamate (Fremeau et al., 2002; Gras et al., 2002; Schafer et al.,
2002; Takamori et al., 2002). VGLUT3 is expressed by cholinergic
interneurons in the dorsal and ventral striatum, subpopulations
of GABAergic basket cells in the cortex and hippocampus, and
serotoninergic neurons (for review, see El Mestikawy et al., 2011).
However, It should be kept in mind that VGLUT1 and VGLUT2
as well are expressed by “non-glutamatergic” neurons (Boulland
et al., 2009; Fattorini et al., 2009; Zander et al., 2010; Ren et al.,
2011).
The almost non-overlapping distribution of the 3VGLUTs
delineates three complementary glutamatergic systems. VGLUT1
and VGLUT2 play major neurophysiological roles in virtually all
major neuronal circuits, while VGLUT3 is involved in more sub-
tle modulation of local transmission (for review see El Mestikawy
et al., 2011).
The widespread distributions of VGLUT1-3 in rodent CNS
suggest their involvement in the regulation of sensori-motor,
cognitive and mood processes. Hence, it can be surmised that
alterations in the expression of these proteins may underlie sig-
nificant aspects of human neurolopathologies. Indeed, recent
postmortem studies have highlighted alterations in VGLUT1 and
VGLUT2 expression in mood disorders and psychosis (Oni-
Orisan et al., 2008; Uezato et al., 2009; Eastwood and Harrison,
2010) as well as in neurological disorders such as Parkinson dis-
ease, Alzheimer disease and epilepsy (Kirvell et al., 2006; Kashani
et al., 2007, 2008; Van Der Hel et al., 2009). These studies mea-
sured VGLUT1-3 mRNA or VGLUT1 and VGLUT2 protein in
cortical or subcortical areas. Unfortunately, the significance of
such results is limited by the fact that our current anatomical
knowledge of VGLUT-defined glutamatergic subsystems in the
human brain is partial at best. The aim of the present study was
thus to characterize the distributions of VGLUT1-3 transcripts
and proteins in major regions of the human brain.
MATERIALS AND METHODS
HUMAN BRAIN SAMPLES
This study was approved by the Douglas Institute Research
Ethics Board, and written informed consent from next-of-kin
was obtained in each case. Postmortem brain samples from six
caucasian individuals (Table 1) were provided by the Douglas-
Bell Canada Brain Bank (www.douglasbrainbank.ca). Three of
the individuals died from accidents or natural causes, with one
having been diagnosed with major depression and two who
had no history of neurological nor psychiatric illness. The two
other individuals committed suicide during a depressive episode
(Table 1). After extraction, brains were immediately placed at
4◦C, rapidly sent to the Douglas-Bell Canada Brain Bank where
they were sliced into thick sections, rapidly frozen and stored
at −80◦C until further use. The postmortem refrigeration delay,
i.e., the time between death and storage of the body at 4◦C at the
morgue, was of 15.5 ± 8.6 h (±SEM) on average. Frozen sam-
ples from the following brain regions were dissected from the
left hemisphere by expert brain bank staff, cut on a cryostat in
10µm-thick serial sections, and processed for in situ hybridiza-
tion or immunoautoradiography (IAR), as detailed below: cere-
bral cortex (Brodmann areas [BAs] 4 and 9), hippocampus,
striatum, amygdala, cerebellum, substantia nigra, thalamus,
raphe.
IN SITU HYBRIDIZATION
In situ hybridization was performed as recommended by
Oramacell (Paris, France) and as previously reported (Gras
et al., 2008). In brief, sense or antisense oligonucleotides spe-
cific for human VGLUT1, VGLUT2, or VGLUT3, the dopamine
(DAT) or serotonin (SERT) transporters (Table 3) (generated
by Oramacell) were labeled with [35S]-dATP (GE Healthcare)
using terminal deoxynucleotidyl transferase (GE Healthcare) to
a specific activity of 1–3 × 108 dpm/mg. On the day of the
experiment, fresh frozen section (10µm) were fixed in 3.7%
formaldehyde in phosphate-buffered saline (PBS), washed with
PBS, rinsed with water, dehydrated in 50 and 70% ethanol, and
air-dried. Sections were then covered with 140µl of hybridization
medium (Oramacell, Paris, France) containing 1.4µl of the
Table 1 | Subject information.
Subject Gender Age (years) Diagnosis Cause of death RD (h)
135 Male 18 Nil Natural death cardiovascular* 2.0
138 Female 66 Nil Car accident* 57.6
146 Male 26 SCZ Suicide* 3.9
152 Female 49 MDD Suicide* 14.7
155 Male 31 MDD Natural death cause unknown* 9.2
513 Male 72 Nil Heart attack 5.0
*As recorded by the coroner. MDD, major depressive disorder; Nil, no psychiatric nor neurological disorders; RD, refrigeration delay; SCZ, schizophrenia.
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Table 2 | List of oligonucleotides used for in situ hybridization.
HUMAN VGLUT1
Antisense oligonucleotides
HV1-AS1: GGGACTCGTAGGAGACGAGCAGCCAGAACAGGTAC
HV1-AS2: GAGAGCACGACCCGCTAGCTTCCGAAACTCCTCCT
HV1-AS3: GAGCAGGGTTCCTTGACACTGTCACTCAGGCCAG
HV1-AS4: CCCCGTAGAAGATGACACCTCCATAGTGCACCAGGG
Sense oligonucleotides
HV1-S1: GTACCTGTTCTGGCTGCTCGTCTCCTACGAGTCCC
HV1-S2: AGGAGGAGTTTCGGAAGCTAGCGGGTCGTGCTCTC
HV1-S3: CTGGCCTGAGTGACAGTGTCAAGGAACCCTGCTC
HV1-S4: CCCTGGTGCACTATGGAGGTGTCATCTTCTACGGGG
HUMAN VGLUT2
Antisense oligonucleotides
HV2-AS1: GCTTCTTCTCCAGACCCCTGTAGATCTGGCCGAG
HV2-AS2: GAAGGGGAGTATCCGGTGGCAAAGAGCGCAAGCAG
HV2-AS3: CCCCAAAAGAAGGAACCGTGGATCATCCCCACGG
HV2-AS4: CTTTCTCCTTGATGACCTTGCCCCCGCGGTGGAT
Sense oligonucleotides
HV2-S1: CTCGGCCAGATCTACAGGGTGCTGGAGAAGAAGC
HV2-S2: CTGCTTGCGCTCTTTGCCACCGGATACTCCCCTTC
HV2-S3: CCGTGGGGATGATCCACGGTTCCTTCTTTTGGGG
HV2-S4: ATCCACCGCGGGGGCAAGGTCATCAAGGAGAAAG
HUMAN VGLUT3
Antisense oligonucleotides
HV3-AS1: CGGCTTCTCTCCAAAGGTGGTGCCCACTTA
HV3-AS2: AGCCAACCACCAGGAGTAAGGTTGCCTCCATGCC
HV3-AS3: CCCCTCCCAATATTTGGACCTCTGGCAAGCTGGG
HV3-AS4: GGACCATCCAATGTACTGCACCAACACCCCAGCC
Sense oligonucleotides
HV3-S1: GGAGTAAGTGGGCACCACCTTTGAGAGAAGCCG
HV3-S2: GGCATGGAGGCAACCTTACTCCTGGTGGTTGGCT
HV3-S3: CCCAGCTTGCCAGAGGTCCAAATATTGGGAGGGG
HV3-S4: GGCTGGGGTGTTGGTGCAGTACATTGGATGGTCC
HUMAN DAT
Antisense oligonucleotides
DAT1AS1: GACTTCCTGGGGTCTTCGTCTCTGCTCCCTCTAC
DATAS2: GTAGGCCAGTTTCTCTCGAAAGGACCCAGGCAGG
DATAS3: GGTATGCTCTGATGCCGTCTATGGCTCCAGGGAG
DATAS4: GCCTGAGTGGCAGTAGCCTGAGCTGGTTTCAAGG
DATAS5: GTTGGCCCAGTCGGGGAAGATGTAGGCTCCGTAGT
Sense oligonucleotides
DAT1S1: GTAGAGGGAGCAGAGACGAAGACCCCAGGAAGTC
DATS2: CCTGCCTGGGTCCTTTCGAGAGAAACTGGCCTAC
DATS3: CTCCCTGGAGCCATAGACGGCATCAGAGCATACC
DATS4: CCTTGAAACCAGCTCAGGCTACTGCCACTCAGGC
DATS5: ACTACGGAGCCTACATCTTCCCCGACTGGGCCAAC
HUMAN SERT
Antisense oligonucleotides
humSERT-AS1: AGCCACTAGGGTGGTGGTGGTCGCTGGGATAGAGT
humSERT-AS2: CCTCCGAGCTCTCTATCGTCGGGATTGACACGTC
humSERT-AS3: CAGGACCCCAAAGCCCGGACCAAGAGAGAAGAAG
humSERT-AS4: GAACAGGAGAAACAGAGGGCTGATGGCCACCCAG
(Continued)
Table 2 | Continued
Sense oligonucleotides
humSERT-S1: ACTCTATCCCAGCGACCACCACCACCCTAGTGGCT
humSERT-S2: GACGTGTCAATCCCGACGATAGAGAGCTCGGAGG
humSERT-S3: CTTCTTCTCTCTTGGTCCGGGCTTTGGGGTCCTG
humSERT-S4: CTGGGTGGCCATCAGCCCTCTGTTTCTCCTGTTC
labeled oligonucleotide. Slides were incubated 16 h at 42◦C,
washed 2 × 15min in saline sodium citrate buffer (SSC 1X)
and dithiothreitol (DTT, 10mM) at 53◦C, 2 × 15min in SSC
0.5X, dehydrated in ethanol, air-dried and exposed to a BAS-SR
Fujifilm Imaging Plate for 7–10 days for VGLUT1 and VGLUT2,
21 days for VGLUT3, 14 days for the dopamine transporter (DAT)
and for 4 days for the serotonin transporter (SERT) mRNA.
The plates were scanned with a Fujifilm BioImaging Analyser
BAS-5000. Each marker was investigated with a combination of
4–5 antisense or sense oligonucleotides (Table 2). In preliminary
experiments, each antisense or sense oligonucleotide was incu-
bated individually or as pool of sense or antisense nucleotides
for a given marker. A labeling was considered specific when: (i)
the distribution observed for each individual oligonuleotide were
similar as the one obtained with combined 4 oligonucleotides
and (ii) no labeling was obtained with corresponding sense
nucleotides.
IMMUNOAUTORADIOGRAPHY
To visualize proteins, immunoautoradiography (IAR) was per-
formed as previously described (Kashani et al., 2007, 2008).
Selective antibodies against VGLUT1 and VGLUT2 were obtained
by immunization of rabbits with the corresponding peptides,
as described previously (Herzog et al., 2001; Kashani et al.,
2007, 2008). To detect VGLUT3 in human samples an anti-
serum was developed by immunizing rabbits with the N-
CEEIELNHESFASPKKKM-C peptide fused to the Keyhole limpet
haemocyanin (AgroBio, Villeny, France, http://www.agro-bio.
fr/). The anti-VGLUT3 antiserum was affinity purified on an
Affigel-10 (Biorad, Richmond, CA) matrix coupled to the N-
CEEIELNHESFASPKKKM-C peptide as described (Kashani et al.,
2007). The specificity of the newly developed serum was assessed
by comparing the distribution of VGLUT3-positive immuno-
labeling obtained with the serum newly produced against a
human peptide (in rabbit) and a previously validated rodent
anti-VGLUT3 (in guinea pig, Gras et al., 2008; Amilhon et al.,
2010; Miot et al., 2012). Immunofluorescence experiments were
conducted as previously described on wildtype or VGLUT3-
nul mouse brain (Figure 1; Gras et al., 2008; Amilhon et al.,
2010; Miot et al., 2012). As shown in Figures 1A–C,E–G,I–K the
immunodistribution of the new anti-human VGLUT3 antiserum
overlapped with the known labeling of VGLUT3 in both
mouse hippocampus and striatum. Furthermore, no labeling
was observed with the new anti-human VGLUT3 antiserum
on sections of mouse brain that no longer expressed VGLUT3
(Figures 1D,H,L; Gras et al., 2008). This experiment demon-
strated that the new serum binds to VGLUT3 and rules out
cross-reactivity with VGLUT1 and VGLUT2 or any other brain
protein.
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FIGURE 1 | Specificity of the newly developed anti-human VGLUT3
antiserum. The distribution of VGLUT3-positive immunolabeling was
compared between the purified serum newly produced in rabbit against a
human peptide (A,E,I) and a previously validated rodent anti-VGLUT3 in
guinea pig (B,F,J), (Gras et al., 2008; Amilhon et al., 2010; Miot et al., 2012).
Immunofluorescence experiments were conducted as previously described
(Gras et al., 2008; Amilhon et al., 2010; Miot et al., 2012) on sections taken at
the level of the striatum (A–D) or hippocampus (E–L) of wild-type
(A–C,E–G,I–K) or VGLUT3-null mice (D,H,L). The newly developed
anti-human VGLUT3 was visualized with red fluorescence (anti rabbit
IgG-Alexa fluor 555) and the rodent isoform with green fluorescence
(anti-guinea pig IgG-Alexa fluor 488). The merged channels are shown in (C)
for the caudate-putamen and in (G,K) for the hippocampus. Scale bar (in L):
100µm in (A–D), 30µm in (E–H), and 10µm in (I–L). Abbreviations: CA3,
CA3 field of the pyramidal layer of the hippocampus; cc, corpus callosum;
CPu, caudate putamen; Cx, cerebral cortex.
Anti-VGLUT1 was used at 1:2000; anti-VGLUT2 affinity puri-
fied antiserum at 1:4000 (Kashani et al., 2007, 2008) and the
affinity purified anti-VGLUT3 at 1:4000.
On the day of the experiment, fresh frozen sections (10µm)
were fixed in 4% formaldehyde in PBS, washed with PBS, and
preincubated in PBS containing 3% bovine serum albumin, 1%
normal goat serum and 1mM NaI (buffer A) for 1 h. Sections
were incubated with buffer A supplemented with polyclonal
rabbit anti-VGLUT1-3 antisera overnight at 4◦C, followed by
anti-rabbit [125I]-IgG (GE Healthcare lifesciences, 100 mCi/ml)
for 2 h. Sections were exposed to X-ray films (Biomax MR,
Kodak, France) for 24 h, and images were digitized using a
PowerLook 100 Umax scanner and analyzed with Multi Gauge
Software.
IMMUNOHISTOCHEMISTRY
Immunohistochemistry detection of VGLUT1-3 on human
brain sections was performed as previously described with
minor modifications. Paraffin embedded sections (5µm) of
the cerebellum were obtained from formalin-fixed brains
as already described (Torres-Platas et al., 2014). VGLUT1-
3 immunostaining was performed with the anti-VGLUT1
antiserum (1:500 dilution) as described previously (Kashani
et al., 2008) and then processed with biotinylated goat anti-
rabbit IgG (1:500 dilution), streptavidine (1:1000 dilution)
and 3′3-diaminobenzidine reagents (Jackson Immunoresearch,
Brulington Ontario, Canada). Images were obtained with a Zeiss
Axioscop microscope.
RESULTS
GENERAL CONSIDERATIONS
The overall regional distributions of VGLUT1-3 mRNA and
proteins were highly similar between subjects (Table 3), and only
slight inter-individual variability in the intensity of signals was
noticed, irrespective of gender, age, presence/absence of psychi-
atric disorder, or cause of death.
REGIONAL VGLUT1-3 mRNA AND PROTEIN DISTRIBUTIONS
Cerebral cortex (BA4, BA9)
The expression patterns of each of the three VGLUTs were con-
served in both motor (BA4) and prefrontal associative cortex
(BA9) (Figure 2). VGLUT1 mRNA was absent in upper lay-
ers but abundant in layers V–VI, with varying intensity levels.
Sparse labeling was also occasionally observed in the underlying
white matter. VGLUT1 protein detected by IAR was strongly and
homogeneously distributed throughout the cortical thickness, but
absent in white matter.
VGLUT2 mRNA was restricted to a band of cells spanning
lower layer V. This distribution was mirrored by the presence
of a more abundant cortical VGLUT2-immunoreactive material
in layer V. The other cortical layers were uniformly immunore-
active but less intensely than layer V. In contrast to VGLUT1
and VGLUT2, VGLUT3 mRNA was only observed in scarce cells
across the gray matter. VGLUT3 protein, however, was observed
throughout the cortex with particular abundance in upper and
lower layers, above and below of a band of lower intensity in
mid-cortex.
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Table 3 | Distribution of VGLUT1-3 transcripts and proteins in various area of the human brain.
Transporter VGLUT1 VGLUT2 VGLUT3 Subject
Region mRNA Protein mRNA Protein mRNA Protein
Cerebral cortex + + + + + + + ++ + ++ 146
Hippocampus + + + + + + N.D. ++ + + + + 146 (Figure 3)
155 (Figure 4)
Amygdala + (LA) + + + N.D. ++ N.D. ++ 135
Basal Ganglia N.D. + + + N.D. + + + + + + + 152
155
Habenula
SNC
N.D.
N.D.
+
+
+ + +
N.D.
+ + +
+ + +
N.D.
N.D.
+ + +
+ + +
146
Thalamus N.D. ++ + + + ++ N.D. N.D. 138
Raphe ++
(Pons)
++ + + +
(Pons)
+ + + ++ + + + 146
Cerebellum + + +
(Gcl)
+ + + N.D. + + + N.D. N.D. 146
LA, lateral amygdala; Gcl, granular cell layer of the cerebellum; N.D., not detected.
FIGURE 2 | Distribution of VGLUT1-3 mRNA and protein in cerebral
cortical Brodmann areas (BA)4 and BA9. Boxed regions are enlarged and
shown in negative.
Hippocampus
In the hippocampal formation, VGLUT1 mRNA was detected
in the pyramidal layer of Cornu Ammonis (CA1-3) fields, in
the granule cell layer of the dentate gyrus (DG), as well as in
sparse cells across the hilus (Figure 3). Weak levels of transcripts
were observed in the presubiculum. VGLUT1 protein was much
more widely distributed, with strong immunoreactivity observed
throughout gray matter, except in the granule cell layer of the DG
and in white matter tract of the stratum lacunosam molecular
above the molecular layer of the DG.
Although VGLUT2 mRNA was not detected in the hippocam-
pus, the protein was very strongly expressed in the molecular
layer of the DG, as well as in the mossy fiber pathway and in the
subiculum.
VGLUT3mRNAwas only expressed in scattered cells through-
out the hippocampal formation, except within the CA pyrami-
dal cell layer and granule cell layer of the DG. The pattern of
VGLUT3-IR was radically different, with more widespread distri-
bution in gray matter displaying particularly strong signal in the
outer DG granule cell layer, hilus, and mossy fiber pathway.
These patterns of expression were observed at various levels of
the anteroposterior axis of the hippocampus (Figure 4).
Amygdala
Of the three transporters examined, VGLUT1 was the only one
to display mRNA expression in the amygdala, with very faint
signal being mostly restricted to the lateral amygdala. In con-
trast, all three VGLUT proteins were labeled in the amygdala.
Immunoreactivities were prominent in the basolateral complex,
although VGLUT3-IR was weaker than VGLUT1- and VGLUT2-
IR (Figure 5).
Basal ganglia
VGLUT1 and VGLUT2 transcripts were absent from basal
ganglia whereas VGLUT3 mRNA was detected in sparse cells
distributed in the caudate the putamen and the nucleus accum-
bens (Figure 6). Immunoreactivity was abundant for all three
VGLUT proteins in the caudate, putamen, and nucleus accum-
bens. In the globus pallidus, VGLUT1-IR was absent, whereas
VGLUT2 and VGLUT3 were weakly expressed in both exter-
nal and internal segments. These patterns of expression were
observed throughout the anteroposterior axis.
Dopaminergic cells from the substantia nigra pars com-
pacta (SNC) were readily observed following in situ hybridiza-
tion performed with antisense oligonucleotides targeting DAT
(Figure 7). None of the 3VGLUTs was found to display
mRNA expression in adjacent sections of the substantia nigra.
However, all three transporters presented diffuse IR with
transporter-specific intensities. Thus, VGLUT1 and VGLUT3
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FIGURE 3 | Distribution of VGLUT1-3 mRNA and protein in the
hippocampal formation. Boxed regions are enlarged and shown in
negative. Abbreviations: CA1–3, fields of the pyramidal layer of the
hippocampus; DG, dentate gyrus; Hil, hilus of the dentate gyrus; mol
DG, molecular layer of the dentate gyrus; PHG, parahippocampal gyrus;
S, subiculum.
displayed weak and strong immunoreactivities, respectively,
whereas VGLUT2 presented intermediate labeling. The only
labeling heterogeneity observed within this nucleus was for
VGLUT3-IR, which seemed stronger in the SN pars medialis
(Figure 7).
Habenula
The habenular complex displayed strong content of VGLUT2
mRNA transcripts, and absence of VGLUT1 and VGLUT3
mRNAs. All three VGLUT proteins were labeled in the habe-
nula. VGLUT2-IR was very strong in both the lateral and medial
habenula, VGLUT3-IR was high and moderate in the medial and
lateral portions of the habenula, respectively, and faint VGLUT3-
IR was restricted to the medial part of the complex (Figure 7).
VGLUT2mRNAwas also observed in sparse cells located ventrally
to the habenula.
Thalamus
Of the three VGLUTs, only VGLUT2 mRNA was found to be
expressed in the thalamus (Figure 8). It was mainly present in
scattered cells in the ventral lateral posterior (VLP) nucleus as well
as the in the ventral posterior lateral (VPL) nucleus. Moderate
VGLUT2-IR was moderate in the VLP, but extended beyond the
extent of transcript distribution. VGLUT2-IR was also observed,
albeit more weakly, in the mediodorsal thalamic nucleus. Despite
the absence of transcript in this region, VGLUT1 protein was
clearly expressed in all thalamic nuclei in the sampled region, with
the exception of the reticular nucleus. VGLUT1-IR was strongest
in the mediodorsal nucleus. Very faint and diffuse VGLUT3-
IR was detected in the thalamus, with no particular pattern of
expression.
Raphe
Serotonergic neurons were observed by SERT ISH in the
raphe. This area (raphe dorsalis) was partially labeled by
VGLUT3 ISH, but did not display VGLUT1 nor VGLUT2
mRNA (Figure 9). This indicates that VGLUT3 is expressed
only in a subset of 5HT neurons, as previously described
in rodents (Kiyasova et al., 2011). In the same sections,
the pons was found to be strongly labeled by VGLUT1
and VGLUT2 ISH, whereas VGLUT3 ISH revealed a complete
absence of transcript. In contrast, all three VGLUT proteins were
distributed in the pons in a similar and overlapping fashion, but
with varying degrees of intensity. Thus, VGLUT1 immunoreac-
tivity was the strongest, followed by VGLUT3- and VGLUT2-
immunoreactivity (Figure 9).
Cerebellum
In the cerebellum, VGLUT1 mRNA was detected only in the
granule cell layer (Figure 10). In contrast, the protein was
more widespread, with very dark and uniform immunoreac-
tivity in the molecular layer. The granule cell layer presented
VGLUT1-IR punctate labeling corresponding to mossy fiber ter-
minals. Finally, white matter contained faintly stained cell bodies
reminiscent of interstitial cells. Although VGLUT2 mRNA was
not detected in the cerebellum, protein was found through-
out this region, but with a distribution that differed markedly
from that of VGLUT1. The granule cell layer displayed the
strongest signal, with VGLUT2-IR confined to mossy fiber ter-
minals. The fainter immunoreactivity in the molecular layer
was limited to sparse varicose fibers. As for VGLUT3 neither
its transcript nor the protein were detected in the cerebellum.
None of the VGLUTs (mRNA or protein) were expressed in the
Purkinje cells.
DISCUSSION
The anatomical distribution of VGLUTs has been thoroughly
described in rodents (see for example, Ni et al., 1995; Bellocchio
et al., 1998, 2000; Aihara et al., 2000; Fremeau et al., 2001, 2002,
2004a,b; Gras et al., 2002, 2005, 2008; Kaneko and Fujiyama,
2002; Varoqui et al., 2002; Herzog et al., 2004; Hioki et al.,
2004). However, only a few studies have been conducted in the
human brain. Some of these studies analyzed the distribution
of mRNA coding for VGLUTs (such as McCullumsmith and
Meador-Woodruff, 2003; Oni-Orisan et al., 2008; Uezato et al.,
2009; Van Der Hel et al., 2009); or investigated the presence
of the proteins with subtype specific antisera (such as Kirvell
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FIGURE 4 | Distribution of VGLUT1-3 proteins at various levels of the
antero-posterior axis of the hippocampus. Sections immunolabeled for
VGLUT1, VGLUT2, and VGLUT3 were obtained at anatomical levels
corresponding approximately to etched lines I-IV. Abbreviations: CA1–3, fields
of the pyramidal layer of the hippocampus; DG, dentate gyrus; Ent, entorhinal
cortex; FuG, fusiform gyrus; Hil, hilus; MolDG, molecular layer of the dentate
gyrus; PaS, parasubiculum; PRC, perirhinal cortex; PrS, presubiculum; S,
subiculum.
et al., 2006; Kashani et al., 2007, 2008; Oni-Orisan et al., 2008;
Van Der Hel et al., 2009) in a few brain regions. The cur-
rent study aimed at localizing mRNA and protein of all three
VGLUTs in various regions of the human brain, using respectively
in situ hybridization and immunoautoradiography with VGLUT
subtype-specific antisera. For this purpose, we developed the first
human anti-VGLUT3 antiserum. This new anti-VGLUT3 pro-
vided the exact same immunolabeling pattern in rodent brain
as that of a previously validated anti-mouse VGLUT3 antibody
(Gras et al., 2008; Amilhon et al., 2010; Miot et al., 2012). A fur-
ther indication of this serum’s specificity was that it immunola-
beled identical brain regions in rodents and humans, as discussed
below. Furthermore, no labeling was observed when this anti-
serum was used on sections from mice no longer expressing
VGLUT3 (Gras et al., 2008; Amilhon et al., 2010). These results
strongly suggest that the newly developed antisera specifically rec-
ognize VGLUT3 and not the closely related VGLUT1 or VGLUT2
subtypes.
Our results are in line and extend previously published results.
We found that transcripts coding for VGLUT1 and VGLUT2
were easily visualized. Interestingly, VGLUT1 and VGLUT2 tran-
scripts are absent from area where both proteins are abun-
dantly expressed (such as the caudate-putamen for example).
This mismatch has been previously reported in rodent (Herzog
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FIGURE 5 | Distribution of VGLUT1-3 mRNA and protein in the amygdala. In addition to the in HIS and immunoautoradiographic labeling, the histological
staining of an adjacent section is shown on the left. Abbreviation: LA, lateral amygdala.
et al., 2001) and reflects the fact that vesicular glutamate
transporters are targeted to presynaptic terminals of principal
neurons.
In human brains, VGLUT3 mRNA was hardly detected in
some areas given weak signals and the small numbers of cells syn-
thesizing this transcript. In contrast to VGLUT1 and VGLUT2,
VGLUT3 transcript is often colocalized with the protein (in the
hippocampus or caudate-putamen for example). This result sug-
gests that, VGLUT3 has a discrete distribution in the human
brain, similar to that previously described in rodents (Gras et al.,
2002; Herzog et al., 2004).
As in rodents (Herzog et al., 2004), VGLUT3 mRNA was
absent from the thalamus, the substantia nigra and the cerebellum
whereas it was detected in sparse cells in the cortex, hippocampus,
caudate-putamen, and in a more concentrated cell population
within the raphe. The distribution of VGLUT3 transcript strongly
suggests a localization in GABAergic interneurons in cerebral cor-
tex and hippocampus, and in cholinergic interneurons in the
caudate-putamen. This indicates a highly conserved expression
pattern between rodents and humans. In the raphe, the VGLUT3-
positive cell population appeared to be intermingled with 5-HT
neurons but not totally overlapping the distribution of SERT
mRNA. Here again suggesting that, as in rodents, VGLUT3 is
expressed in a subpopulation of 5-HT neurons (Kiyasova et al.,
2011). However, double-labeling experiments will be required
to fully confirm these hypotheses. In contrast to the mRNA,
VGLUT3-IR signal was found throughout gray mater areas with
the exception of the cerebellum and thalamic nuclei. Interestingly,
in the cerebral cortex, VGLUT3 seems to be more abundantly
present in layer I–III and V–VI. This immunolabeling pattern is
also highly similar to the one reported in rodent brain (Herzog
et al., 2004; Somogyi et al., 2004). This implies that VGLUT3 is
likely involved in the regulation of locomotor activity, reward and
mood in humans, as previously suggested by studies conducted
on mutant mouse models (Seal and Edwards, 2006; Gras et al.,
2008; Amilhon et al., 2010). Since VGLUT3 is very discretely dis-
tributed in the human brain, it is a likely candidate for targeted
treatments of specific pathologies such as Parkinson’s disease,
addiction, or mood disorders.
VGLUT1 and VGLUT2 patterns of mRNA expression
in human brains corresponded to prominent cortical and
subcortical glutamatergic systems, as previously described in
rodents. In cerebral cortex, VGLUT1 mRNA displayed the most
intense VGLUT signal. It was concentrated in layers V-VI, and
thus presumably associated with pyramidal neurons project-
ing to subcortical structures. VGLUT2 mRNA, however, was
rather weakly expressed in cortex, with signal being limited to
a small band of cells in the middle layers. In contrast, protein
expression for both transporter subtypes was strong in cere-
bral cortex. VGLUT1-IR yielded the strongest and most uni-
form staining in neocortex, spanning all layers homogeneously.
VGLUT2-IR was also found throughout the cortical thickness,
but much more weakly, except for a dense IR band in mid-
cortex that colocalized with its mRNA distribution. This band
also likely corresponded to layer V pyramidal neurons. The com-
bined intensities of VGLUT1- and VGLUT2-IR throughout the
cortical thickness clearly reflects the abundance of cortical and
subcortical glutamatergic axon terminating in this structure. In
the hippocampus, VGLUT1 (but not VGLUT2) was also asso-
ciated with projection neurons. VGLUT1 mRNA sharply out-
lined the CA fields as well as the dentate gyrus, with strong
signal in pyramidal neurons as well as granule cells. Thus, as
in rodents, VGLUT1- and VGLUT2-IR suggests that VGLUT1
is the major vesicular glutamate transporter in the hippocam-
pus and that VGLUT2 has only a discrete distribution in this
area.
In subcortical regions, VGLUT1 and VGLUT2 displayed vari-
able expression patterns. In the basal ganglia, although mRNAs
for these transporters were completely absent, VGLUT1- and
VGLUT2-IR were very intense in the caudate, putamen as well
as the nucleus accumbens, and moderate in the substantia nigra.
As previously described in rodents, VGLUT2-IR in the globus
pallidus was also of moderate intensity, whereas VGLUT1 was
absent. In the amygdala, the basolateral amygdaloid complex was
the only region strongly delineated by VGLUT1- and VGLUT2-
IR, as well as by VGLUT1 mRNA expression. Of note was
the particularly high VGLUT2 mRNA and protein expression
in the habenular complex, and moderate VGLUT1-IR in the
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FIGURE 6 | Distribution of VGLUT1-3 mRNA and protein in the
caudate-putamen region. Boxed regions are enlarged and shown in
negative. Abbreviations: Ac, nucleus accumbens; Cd, caudate nucleus; EGP,
external globus pallidus; GP, globus pallidus; ic, internal capsule; IGP, internal
globus pallidus; LH, lateral hypothalamus; lml, lateral medullary lamina of
globus pallidus; Pu, putamen.
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FIGURE 7 | Distribution of VGLUT1-3 mRNA and protein in substantia
nigra. Substantia nigra pars compacta (SNC) was identified by detection of
the transcript coding for the dopamine transporter (DAT). Abbreviations: fr,
fasciculus retroflexus; lHb, lateral habenula; mHb, medial habenula; R, red
nucleus.
FIGURE 8 | Distribution of VGLUT1-3 mRNA and protein in the
thalamus. Abbreviations: Cd, caudate nucleus; MD, mediodorsal thalamic
nucleus; Rt, reticular thalamic nucleus; VLP, ventral lateral posterior
thalamic nucleus; VPL, ventral posterior thalamic nucleus.
lateral habenula. The only VGLUT mRNA (weakly) expressed
in the thalamus was that coding for VGLUT2, with propor-
tionally moderate immunoreactivity. The latter was uneven at
the anatomical level examined, with sharp differences between
thalamic nuclei. Heterogeneous VGLUT1-IR was also observed
between nuclei, but its distribution did not match that of
VGLUT2-IR.
The only VGLUT mRNA detected in the cerebellum was
VGLUT1 mRNA strongly expressed in but confined to the gran-
ule cell layer. VGLUT1 and VGLUT2 proteins, however, were
abundantly expressed and presented a complementary distribu-
tion along cerebellar layers. This strong IR is thus mainly pro-
vided by cerebellar afferents, among which the pontine nucleus
was found to express high levels of VGLUT1 and VGLUT2
mRNA.
FIGURE 9 | Distribution of VGLUT1-3 mRNA and protein in the raphe.
Serotoninergic cells in the dorsal raphe nucleus (DR) were identified by
detection of the transcript coding for the serotonin transporter (SERT).
Similar to rodents (Herzog et al., 2004), VGLUT3 mRNA was
absent from the thalamus, the substantia nigra and the cere-
bellum whereas it was detected in sparse cells in the cortex,
hippocampus, caudate-putamen, and in a more concentrated cell
population within the raphe. The distribution of VGLUT3 tran-
script strongly suggests a localization in GABAergic interneurons
in cerebral cortex and hippocampus, and in cholinergic interneu-
rons in the caudate-putamen. Again, this indicates a highly
conserved expression pattern between rodents and humans. In
the raphe, the VGLUT3-positive cell population appeared to
be intermingled with 5-HT neurons but not totally overlap-
ping the distribution of SERT mRNA. Here again suggesting
that, as in rodents, VGLUT3 is expressed in a subpopulation
of 5-HT neurons. However, double-labeling experiments will
be required to fully confirm this hypothesis. In contrast to the
mRNA, VGLUT3-IR signal was found throughout gray mater
areas with the exception of the cerebellum and thalamic nuclei.
Interestingly, in the cerebral cortex, VGLUT3 seems to be more
abundantly present in layer I–III and V–VI. This immunolabeling
pattern is also highly similar to the one reported in rodent brain
(Herzog et al., 2004).
In summary, the anatomical distributions of brain cells
expressing each one of the 3VGLUTs are strikingly different.
In contrast, the proteins are often found within the same
areas (with the exception of the cererbellum and the thala-
mus, in which VGLUT3 was not detected). The regional dis-
tributions of VGLUT transcripts and proteins was found to
be highly similar between human and rodent, suggesting that
these transporters play fundamental roles in brain function that
were conserved with evolution. This knowledge is particularly
important given the previous implication of VGLUTs in cere-
bral pathologies, as it validates the use of rodent models to
uncover the molecular mechanisms underlying human mental
illnesses.
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